Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxymorphone
Drug ID BADD_D01648
Description An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
Indications and Usage For the treatment of moderate-to-severe pain.
Marketing Status approved; investigational; vet_approved
ATC Code N02AA11
DrugBank ID DB01192
KEGG ID D08323
MeSH ID D010111
PubChem ID 5284604
TTD Drug ID D02NSF
NDC Product Code 0406-3433
UNII 9VXA968E0C
Synonyms Oxymorphone | Oxymorphone Hydrochloride | Oxymorphone HCl | Numorphan | Opana
Chemical Information
Molecular Formula C17H19NO4
CAS Registry Number 76-41-5
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspnoea02.11.05.003; 22.02.01.004--
Euphoric mood19.04.02.006--
Eye disorder06.08.03.001---
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Feeling jittery08.01.09.016---
Flatulence07.01.04.002--
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Hallucination19.10.04.003--
Head injury12.01.09.003---
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Ileus07.13.01.001--
Ileus paralytic07.02.05.001---
Immune system disorder10.02.01.001---
Injection site reaction08.02.03.014; 12.07.03.015--
Insomnia17.15.03.002; 19.02.01.002--
Intracranial pressure increased17.07.02.002---
Laryngeal oedema10.01.05.003; 22.04.02.001; 23.04.01.005--
Laryngospasm22.04.02.002--
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Loss of consciousness17.02.04.004---
Lung disorder22.02.07.001---
Memory impairment17.03.02.003; 19.20.01.003--
Menopausal symptoms21.02.02.002---
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages